Sign In
Buy PRVB
$24.98
+0 (+0%)
At Close: Jul 24, 2023
New York, New York--(Newsfile Corp. - July 7, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Provention Bio, Inc. (NASDAQ: PRVB) alleg
New York, New York--(Newsfile Corp. - July 6, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Pro
SHAREHOLDER ALERT: Investigation of Provention Bio Announced by Holzer & Holzer, LLC
01:35pm, Tuesday, 06'th Jul 2021
Atlanta, Georgia--(Newsfile Corp. - July 6, 2021) - Holzer & Holzer, LLC is investigating whether Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) complied with federal securities
Here's Why Provention Bio Stock Is Diving Today
01:00pm, Tuesday, 06'th Jul 2021
The company's latest letter from the FDA wasn't what investors had hoped for.
Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today
10:16am, Tuesday, 06'th Jul 2021
Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ: ADXS) are among the bi
Provention Bio's Teplizumab Application Receives CRL For Type-1 Diabetes; Stock Drops
07:55am, Tuesday, 06'th Jul 2021
The FDA has issued a Complete Response Letter (CRL) to Provention Bio Inc's (NASDAQ: PRVB) teplizumab marketing application seeking approval for the delay of clinical type 1 diabetes (T1D) in at-r
RED BANK, N.J., July 6, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that th
New York, New York--(Newsfile Corp. - July 5, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and
New York, New York--(Newsfile Corp. - July 5, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Provention Bio, Inc. (NASDAQ: PRVB) allegin
New York, New York--(Newsfile Corp. - July 5, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Pro
New York, New York--(Newsfile Corp. - July 2, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of P
NEW YORK, July 2, 2021 /PRNewswire/ -- WHY: New York, N.Y., July 2, 2021.
NEW YORK, July 01, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB) and certain of i
New York, New York--(Newsfile Corp. - June 29, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Pr
New York, New York--(Newsfile Corp. - June 29, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between Novem
